Where does Nalpropion Pharmaceuticals LLC rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Nalpropion Pharmaceuticals LLC ranks #20,118 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Nalpropion Pharmaceuticals LLC hold?

Nalpropion Pharmaceuticals LLC holds 14 US utility patents granted between 2019 and 2024, spanning 7 technology areas.

What is Nalpropion Pharmaceuticals LLC's Innovation Score?

Nalpropion Pharmaceuticals LLC has an Innovation Score of 32.0 out of 100 (40th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Nalpropion Pharmaceuticals LLC focus on?

Nalpropion Pharmaceuticals LLC's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 14 patents, ranking #1,384 of 6,058 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

Is Nalpropion Pharmaceuticals LLC's patent grant rate increasing or decreasing?

Nalpropion Pharmaceuticals LLC's recent grant velocity is +33% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Nalpropion Pharmaceuticals LLC's patents?

Nalpropion Pharmaceuticals LLC's patents average 17.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Nalpropion Pharmaceuticals LLC patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Nalpropion Pharmaceuticals LLC

USPTO PatentsView assignee record - 14 granted patents across 7 technology areas, recorded in grant years 2019–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Nalpropion ranks #20,118 of 49,997 tracked US assignees by granted-patent volume, with 14 patents across 7 technology areas.

#20,118
of 49,997 US assignees by volume: 40th percentile
by Innovation Score (32.0/100): 17.6
avg claims per patent: +33%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R20118 · US Corporation #20,118 · 14 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-UP · BOOK-FULL

GRANTS-MICRO 14 grants
MID-PACK #20,118/49,997
PHOTO-FINISH Nanjing Horizon…
CPC-NARROW A61P · 7 areas
INNOV-THIN 32.0/100
CLAIMS-RICH 17.6 claims/avg
TYPE-USCORP US Corporation
VEL-UP +33% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Nanjing Horizon Robotics Technology Co., Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Nalpropion’s 32.0 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.4 pts (29%) Velocity 2.7 pts (8%) Breadth 9.4 pts (29%) Claim depth 10.6 pts (33%)

Qualcomm Incorporated · highest

85
Nalpropion Pharmaceu… · this assignee

32
3D Lighting… · lowest

7

What this shows Nalpropion's Innovation Score is 32.0/100 (40th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Nalpropion?

Each dot is one of Nalpropion’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Nalpropion’s own 17.6 claims/patent is ABOVE the 16.7 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Nalpropion vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Nalpropion's grants concentrate

Nalpropion Pharmaceuticals LLC is a focused PatentsView assignee: 7 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2019 (6 grants) versus a trough of 2 in 2020. By volume, Nalpropion sits between NSI International, Inc. and Native Microbials, Inc..

Nalpropion's three-year grant acceleration

Nalpropion Pharmaceuticals LLC shows 4 grants in 2022–2024 against only 10 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

NSI International

14
NTT Data Services

14
Nurix Therapeutics

14
Nutcracker Therap…

14
Nanjing Horizon R…

14
Nanostar

14
National Diversif…

14
Native Microbials

14
Nalpropion Pharma… ◀

14

What this shows Nalpropion holds 14 patents at rank #20,153, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Nalpropion

By rank, the assignees closest to #20,153 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Nalpropion's primary technology class.

Nalpropion's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

32 40th percentile higher than 40% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2019–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table

Nalpropion Pharmaceuticals LLC patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2019	6	42.9%
2020	2	14.3%
2021	2	14.3%
2022	2	14.3%
2024	2	14.3%

Which technologies does Nalpropion Pharmaceuticals LLC patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 14

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 14

A61J - Containers Specially Adapted FOR Medical OR Pharmaceutical PURPOSES; Devices OR Methods Specially Adapted FOR Bringing Pharmaceutical Products Into Particular Physical OR Administering FORMS; Devices FOR Administering Food OR Medicines ORALLY; Baby COMFORTERS; Devices FOR Receiving Spittle 2

B65D - Containers FOR Storage OR Transport OF Articles OR Materials, e.g. Bags, Barrels, Bottles, Boxes, Cans, Cartons, Crates, Drums, Jars, Tanks, Hoppers, Forwarding CONTAINERS; Accessories, Closures, OR Fittings THEREFOR; Packaging ELEMENTS; Packages 2

G01G - Weighing 2

G09B - Educational OR Demonstration APPLIANCES; Appliances FOR Teaching, OR Communicating With, THE Blind, Deaf OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; Diagrams 2

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 2

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Nalpropion Pharmaceuticals LLC's patent record in context - here's where to go next.

Nalpropion Pharmaceuticals LLC's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #20,118 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Nalpropion Pharmaceuticals LLC against NSI International, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 32.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.